All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
Will J&J turbocharge Crucell's vaccine portfolio?
Cormac Sheridan
Published
2010
in
Nature Biotechnology
Save
Cite
View on Nature
Abstract & Figures
Cited By
References
Abstract
Sorry, we couldn't extract an abstract for this paper.
DOI:
10.1038/nbt1210-1223
Topics
Crucell
Diphtheria
Johnson and Johnson
Haemophilus influenzae type b
Pertussis Vaccine
Hepatitis B
Bordetella pertussis
Haemophilus influenzae
Tetanus
Surface Antigens
Hepatitis B Virus
Vaccines, Conjugate
Biological Factors
Adenoviruses
Immunostimulating conjugate (antigen)
Corynebacterium diphtheriae
Infection
Acquired Name
Hemophilus
Herpesvirus 1, Cercopithecine
Cell Culture Techniques
Flow Cytometry
Hepatitis B Surface Antigens
Cytometry
SmithKline Beecham
1 Figure or Table
table 1
Cited By
Sorry, we couldn't extract any citations for this paper.
References
Sorry, we couldn't extract any references for this paper.
Similar Papers
Loading similar papers…
Slides referencing similar topics
(Pneumococcal non-typeable Haemophilus influenzae protein D-Conjugate Vaccine)
Eduardo Ortega-Barría • Oct 20, 2017
Vaccines: Antigens, Adjuvants Autogenous?
Chris Chase + 1 • Aug 27, 2017
TMCM J 1 J 2 Connector Conformal Coat Flow Analysis
Sep 30, 2017
Show More